Novel Aryl- and Heteroarylpiperazines

Use of a compound of the general formula (II′):

• wherein
• R2 is hydrogen or C1-4-alkyl,
• R1 represents
• C1-8-alkyl, C2-8-alkenyl or C2-8-alkynyl, which may optionally be substituted with one or more halogen substituents,
• C3-5-cycloalkyl, C3-7-cycloalkenyl, C3-6-cycloalkyl-C1-3-alkyl or C3-6-cycloalkenyl-C1-3-alkyl, which may optionally be substituted with one or more halogen substituents,
• R1 and R2 together form a C3-6-alkylene bridge,
• A represents
• R3 is hydrogen, halogen, hydroxy, trifluoromethyl, trifluoromethoxy, C1-10-alkyl, C2-10-alkenyl, C3-8-cycloalkyl, C1-6-alkoxy, aryl, aryl-C1-6-alkyl, amino, C1-6-alkylamino, di-C1-6-alkylamino, C3-8-cycloalkyl, C3-8-cycloalkyloxy, cyano, nitro, C1-6-alkylsulfanyl, or C1-6-alkylsulfonyl,
• Z and X independently represent —N═, —C(H)═, —C(F)═, —C(Cl)═, —C(CN)═ or —C(CF3)═,
• W represents —N═ or —C(R10)═,
• Y represents —N═ or —C(R11)═,
• R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 independently represent
• hydrogen, halogen, hydroxy, trifluoromethyl, trifluoromethoxy, —SCF3, amino, cyano, nitro, or —C(═O)NR14R15
• C1-10-alkyl, C2-10-alkenyl, C3-8-cycloalkyl, C1-6-alkoxy, C3-8-cycloalkyl-C1-6-alkoxy, C1-6-alkylamino, di-C1-6-alkylamino, C3-8-cycloalkyloxy, C1-6-alkylsulfanyl, C1-6-alkylsulfonyl, C2-10-alkanoyl, C4-9-cycloalkanoyl, C3-8-heterocyclyl or C4-9-heterocycloalkanoyl, C4-9-heterocycloalkoxy, which may optionally be substituted with one or more substituents selected from R16
• aryl, aryl-C1-6-alkyl, aryl-C1-6-alkoxy or heteroaryl, which may optionally be substituted with one or more substituents selected from R17,
• aroyl, heteroaroyl, aryloxy, heteroaryloxy, arylamino or heteroarylamino, which may optionally be substituted with one or more substituents selected from R18,
• or two of R5, R6, R7, R8, R9, R10, R11, R12 and R13 in adjacent positions together form a C1-6-alkylene bridge or an —O—C1-6-alkylene-O— bridge,
• R14 and R15 are independently hydrogen, C1-6-alkyl, aryl-C1-6-alkyl or R14 and R15 may together form a C3-6-alkylene bridge
• R16 is independently selected from aryl, heteroaryl, C3-8-cycloalkyl, halogen, trifluoromethyl, trifluoromethoxy, NR19R20 and C1-6-alkoxy,
• R17 is independently selected from halogen, hydroxy, trifluoromethyl, trifluoromethoxy, C1-6-alkoxy, C1-6-alkyl, amino, C1-6-alkylsulfonyl, C1-6-alkylamino, di-C1-6-alkylamino, cyano, aryl, heteroaryl and C3-8-cycloalkyl,
• R18 is independently selected from aryl, heteroaryl, C1-10-alkyl, C3-8-cycloalkyl, halogen, trifluoromethyl, trifluoromethoxy, C1-6-alkoxy, cyano, amino, C1-6-alkylamino, di-C1-6-alkylamino and hydroxy,
• R19 and R20 are independently hydrogen or C1-6-alkyl, R19 and R20 may together form a C3-6-alkylene bridge,
• as well as any diastereomer or enantiomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of disorders and diseases related to the histamine H3 receptor.